From: Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Model | PCSK9 1-SD increase | PCSK9 T1 | PCSK9 T2 | PCSK9 T3 |
---|---|---|---|---|
Crude | 1.92 (1.43–2.57)†| 1.00 (Reference) | 2.57 (0.90–7.33) | 4.44 (1.62–12.18)†|
Model 1 | 1.99 (1.46–2.68)†| 1.00 (Reference) | 2.76 (0.96–7.95) | 4.85 (1.74–13.54)†|
Model 2 | 1.95 (1.41–2.70)†| 1.00 (Reference) | 2.94 (1.00–8.63) | 3.93 (1.35–11.42)* |
Model 3 | 1.86 (1.29–2.69)* | 1.00 (Reference) | 3.36 (1.11–10.22)* | 3.76 (1.16–12.27)* |
Model 4 | 1.86 (1.31–2.65)* | 1.00 (Reference) | 3.30 (1.09–10.01)* | 3.70 (1.16–11.82)* |